7 results on '"Gioulbasanis, Ioannis"'
Search Results
2. The Glasgow Prognostic Score (GPS) predicts toxicity and efficacy in platinum-based treated patients with metastatic lung cancer
- Author
-
Gioulbasanis, Ioannis, Pallis, Athanasios, Vlachostergios, Panagiotis J., Xyrafas, Alexandros, Giannousi, Zoe, Perdikouri, Isidora-Eleni, Makridou, Michalitsa, Kakalou, Dionysia, and Georgoulias, Vassilios
- Subjects
- *
SMALL cell lung cancer , *LUNG cancer treatment , *METALS in medicine , *ETIOLOGY of cancer , *METASTASIS , *CANCER-related mortality , *NEUROTOXICOLOGY , *CANCER invasiveness , *PATIENTS - Abstract
Abstract: Purpose: Lung cancer is the most common cause of cancer death. A cumulative prognostic score based on C-reactive protein and albumin, termed the Glasgow Prognostic Score (GPS), indicates the presence of systemic inflammatory response. GPS has been proposed as a powerful prognostic tool for patients with various types of malignant tumors, including lung cancer. The aim of this study was to assess the predictive value of baseline GPS in terms of toxicity and response in lung cancer patients treated with platinum-based chemotherapy. Patients and methods: Patients referred to our institution for consideration of first-line platinum-based treatment were eligible. Demographics and disease-related characteristics were recorded. Toxicity was graded according to NCI CTCAE version 3.0 throughout first-line therapy. GPS was calculated before the onset of treatment and was related to the development of toxicity. Response to first-line therapy and survival data were also collected. Results: Totally, 96 lung cancer patients were accrued. GPS was associated with increased mucositis p =0.004), neurotoxicity (p =0.038), neutropenia (p =0.02), dose reductions or/ and need for granulocyte colony-stimulating factor (G-CSF) support (p =0.005), toxicity-related termination of treatment (p =0.001) and chemotherapy-related toxic deaths (p =0.013). GPS was associated with overall survival (p =0.016) and progression-free survival (p =0.016) as well as response to treatment (p =0.05). Conclusions: Our data demonstrate that GPS assessment is predictive of the most important aspects of platinum-related toxicity and this may partly explain its associations with poor clinical outcome in patients with metastatic lung cancer. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
3. Baseline Plasma Levels of Interleukin-8 in Stage IV Non-Small-Cell Lung Cancer Patients: Relationship With Nutritional Status and Prognosis.
- Author
-
Gioulbasanis, Ioannis, Patrikidou, Anna, Kitikidou, Kyriaki, Papadimitriou, Konstantinos, Vlachostergios, PanagiotisJ., Tsatsanis, Christos, Margioris, AndrewN., Papandreou, ChristosN., Mavroudis, Dimitris, and Georgoulias, Vassilis
- Subjects
- *
LUNG cancer diagnosis , *ACADEMIC medical centers , *BLOOD testing , *CANCER patients , *CHEMOKINES , *CONFIDENCE intervals , *STATISTICAL correlation , *DEMOGRAPHY , *DIET , *PATIENT aftercare , *INTERLEUKINS , *LUNG cancer , *EVALUATION of medical care , *MEDICAL referrals , *NUTRITION , *NUTRITIONAL requirements , *ONCOLOGY , *SURVIVAL analysis (Biometry) , *TUMOR classification , *DATA analysis , *PROPORTIONAL hazards models , *DATA analysis software ,DEVELOPED countries - Abstract
Interleukin (IL)-8 promotes cellular proliferation and angiogenesis in patients with non-small-cell lung cancer (NSCLC) and may be related to cachexia. Our aim was to investigate the relationship of IL-8 levels with nutritional status, and clinical outcome of patients with NSCLC. Patients with metastatic NSCLC referred for first-line therapy were eligible. Baseline IL-8 levels were measured in plasma. The Mini Nutritional Assessment (MNA) was used for the evaluation of the nutritional status, and patients were classified into 3 groups: A (score 24–30) “well nourished,” B (score 17–23.5) “risk of malnutrition,” and C (0–16.5) “malnourishment.” Response to first-line chemotherapy, time-to-tumor progression (TTP), and overall survival (OS) were also recorded. In total, 114 patients (101 males, 88.5%; mean age = 67.5 yr) were evaluated. Performance status was 0–1 in 62% of the patients. According to the MNA, the majority of patients (71%) was either at nutritional risk or malnourished. IL-8 levels were significantly different between MNA groups (P = 0.023) and correlated with TTP (P = 0.013) and OS (P = 0.001) in univariate analysis. Baseline IL-8 levels correlate with the nutritional status of patients with metastatic NSCLC, suggesting that this cytokine may be related with cachexia. [ABSTRACT FROM PUBLISHER]
- Published
- 2012
- Full Text
- View/download PDF
4. Mini Nutritional Assessment (MNA) and biochemical markers of cachexia in metastatic lung cancer patients: Interrelations and associations with prognosis
- Author
-
Gioulbasanis, Ioannis, Georgoulias, Panagiotis, Vlachostergios, Panagiotis J., Baracos, Vickie, Ghosh, Sunita, Giannousi, Zoe, Papandreou, Christos N., Mavroudis, Dimitris, and Georgoulias, Vassilis
- Subjects
- *
NUTRITIONAL assessment , *BIOMARKERS , *CACHEXIA , *METASTASIS , *WEIGHT loss , *LUNG cancer , *HEMOGLOBINS - Abstract
Abstract: Purpose: Lung cancer patients frequently present with weight loss in the context of the cachexia syndrome. Despite its high clinical significance, definite diagnostic criteria of cachexia are lacking. Nutritional screening questionnaires, like the Mini Nutritional Assessment (MNA), have been proposed for the timely diagnosis of the syndrome. The aim of this study was to evaluate the correlation of MNA with laboratory markers of inflammation/cachexia in patients with metastatic lung cancer. The prognostic value of the measured parameters was also examined. Patients and methods: Patients with metastatic lung cancer referred for systemic therapy were eligible. Baseline clinical characteristics were recorded and nutritional status was assessed using MNA. Blood samples were also collected and the following parameters were measured: hemoglobin (Hb), albumin (Alb), C-reactive protein (CRP), ghrelin, adiponectin, leptin and insulin growth factor I (IGF-I). Results: Totally, 115 patients (101 males) [median age 66 years (range 32–86)] were evaluated. According to MNA score, 27 (23.5%) patients were well nourished, 59 (51.3%) were at nutritional risk and 29 (25.2%) were already malnourished at diagnosis. MNA correlated with the following parameters: Hb (p =0.001), albumin (p <0.001), CRP (p =0.002), adiponectin (p =0.037) and leptin (p =0.008). After a median follow up of 38.2 months, multivariate analysis revealed that age (p =0.008), number of metastatic sites (p <0.001), MNA (p =0.044) and leptin (p =0.004) independently correlated with overall survival. Conclusions: Based on the MNA, the majority of patients were either malnourished or at nutritional risk. MNA correlated with laboratory parameters related to inflammation/cachexia and was independently associated with survival. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
5. Non-Platinum-Based First-Line Followed by Platinum-Based Second-Line Chemotherapy or the Reverse Sequence in Patients with Advanced Non-Small Cell Lung Cancer: A Retrospective Analysis by the Lung Cancer Group of the Hellenic Oncology Research Group.
- Author
-
Agelaki, Sofia, Hatzidaki, Dora, Kotsakis, Athanasios, Papakotoulas, Pavlos, Polyzos, Aris, Ziras, Nikolaos, Gioulbasanis, Ioannis, Karampeazis, Athanasios, Agelidou, Athina, Tsiafaki, Xanthi, Chandrinos, Vassilis, Lerikou, Maria, and Georgoulias, Vassilis
- Subjects
LUNG cancer ,DRUG therapy ,PLATINUM ,CANCER cells ,CANCER treatment - Abstract
Background: Non-platinum-containing regimens have been proposed as alternatives to platinum-based doublets in the first-line treatment of patients with non-small cell lung cancer (NSCLC). However, conflicting results about their equivalence have been reported. Methods: We reviewed the records of patients enrolled in randomized controlled first-line trials conducted by the Hellenic Oncology Research Group from February 1997 to September 2006. The outcome of patients treated with first-line non-platinum-based chemotherapy who received platinum-based chemotherapy upon progression (cohort A) or platinum-based first-line chemotherapy followed by non-platinum-containing second-line chemotherapy (cohort B) was retrospectively analyzed. Results: Two-hundred and sixty-seven patients were identified in cohort A, and 123 in cohort B. Median follow-up time was 12.5 and 15.7 months for cohorts A and B. A significantly higher response rate and time to tumor progression (TTP) was recorded for patients treated with platinum-based compared to those receiving non-platinum-based first-line chemotherapy (45.5 vs. 21.3%, p < 0.0001 and 5.8 vs. 3.1 months, p= 0.002, respectively). Platinum-based regimens administered as second-line treatment resulted in a 13.1% response rate. TTP for second-line chemotherapy did not differ significantly between the two cohorts. Median overall survival was 13.3 and 15.7 months for cohorts A and B (p = 0.538). Conclusion: Both sequences resulted in similar efficacy in terms of overall survival. Encouraging median survival was achieved for selected patients with NSCLC who received both first- and second-line chemotherapy. Copyright © 2010 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
6. Prognosis in advanced lung cancer – A prospective study examining key clinicopathological factors.
- Author
-
Simmons, Claribel P., Koinis, Filippos, Fallon, Marie T., Fearon, Kenneth C., Bowden, Jo, Solheim, Tora S., Gronberg, Bjorn Henning, McMillan, Donald C., Gioulbasanis, Ioannis, and Laird, Barry J.
- Subjects
- *
LUNG cancer prognosis , *LUNG cancer diagnosis , *LONGITUDINAL method , *CANCER chemotherapy , *TUMOR markers , *REGRESSION analysis - Abstract
Objectives In patients with advanced incurable lung cancer deciding as to the most appropriate treatment (e.g. chemotherapy or supportive care only) is challenging. In such patients the TNM classification system has reached its ceiling therefore other factors are used to assess prognosis and as such, guide treatment. Performance status (PS), weight loss and inflammatory biomarkers (Glasgow Prognostic Score (mGPS)) predict survival in advanced lung cancer however these have not been compared. This study compares key prognostic factors in advanced lung cancer. Materials and methods Patients with newly diagnosed advanced lung cancer were recruited and demographics, weight loss, other prognostic factors (mGPS, PS) were collected. Kaplan–Meier and Cox regression methods were used to compare these prognostic factors. Results 390 patients with advanced incurable lung cancer were recruited; 341 were male, median age was 66 years (IQR 59–73) and patients had stage IV non-small cell ( n = 288) (73.8%) or extensive stage small cell lung cancer ( n = 102) (26.2%). The median survival was 7.8 months. On multivariate analysis only performance status (HR 1.74 CI 1.50–2.02) and mGPS (HR 1.67, CI 1.40–2.00) predicted survival ( p < 0.001). Survival at 3 months ranged from 99% (ECOG 0–1) to 74% (ECOG 2) and using mGPS, from 99% (mGPS0) to 71% (mGPS2). In combination, survival ranged from 99% (mGPS 0, ECOG 0–1) to 33% (mGPS2, ECOG 3). Conclusion Performance status and the mGPS are superior prognostic factors in advanced lung cancer. In combination, these improved survival prediction compared with either alone. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
7. Corrigendum to “Prognosis in advanced lung cancer – A prospective study examining key clinicopathological factors” [Lung Cancer 88 (2015) 304–309].
- Author
-
Simmons, Claribel P., Koinis, Filippos, Fallon, Marie T., Fearon, Kenneth C., Bowden, Jo, Solheim, Tora S., Gronberg, Bjorn Henning, McMillan, Donald C., Gioulbasanis, Ioannis, and Laird, Barry J.
- Subjects
- *
LUNG cancer , *LUNG diseases - Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.